Literature DB >> 11673528

Loss of PU.1 expression following inhibition of histone deacetylases.

R N Laribee1, M J Klemsz.   

Abstract

Altering chromatin structure by blocking histone deacetylase activity with specific inhibitors such as trichostatin A can result in an up-regulation of gene expression. In this report, however, we show that expression of the ETS domain transcription factor PU.1 is down-regulated in cells following the addition of trichostatin A. The loss of PU.1 is seen at both the mRNA and protein levels in multiple cell lines and is reversible following removal of the drug. More importantly, we show that the loss of PU.1 results in a loss of PU.1 target gene expression, including CD11b, c-fms, Toll-like receptor 4, and scavenger receptor. Chromatin immunoprecipitation analysis of cells treated with trichostatin A showed a significant increase in the acetylation of histone H4, but not histone H3, across approximately 650 bp of the PU.1 promoter region. Our data suggest that the consequences of using drugs that inhibit histone deacetylase activity may be a loss of blood cell development and/or function due to a block in PU.1 gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673528     DOI: 10.4049/jimmunol.167.9.5160

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

Authors:  Anne Rascle; James A Johnston; Bruno Amati
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 2.  Important roles of reversible acetylation in the function of hematopoietic transcription factors.

Authors:  Xiaofang Huo; Junwu Zhang
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

3.  Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells.

Authors:  Atsushi Isono; Tatsuro Katsuno; Toru Sato; Tomoo Nakagawa; Yasutaka Kato; Naoki Sato; Gen'ichiro Seo; Yasuo Suzuki; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

4.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Authors:  Nilamadhab Mishra; Christopher M Reilly; Doris R Brown; Phil Ruiz; Gary S Gilkeson
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

5.  Histone deacetylase 1 activates PU.1 gene transcription through regulating TAF9 deacetylation and transcription factor IID assembly.

Authors:  Wei Jian; Bowen Yan; Suming Huang; Yi Qiu
Journal:  FASEB J       Date:  2017-06-01       Impact factor: 5.191

6.  Gcn5 is required for PU.1-dependent IL-9 induction in Th9 cells.

Authors:  Ritobrata Goswami; Mark H Kaplan
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

7.  HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2.

Authors:  G Schneider; M Reichert; D Saur; R Hamacher; R Fritsch; R M Schmid
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831

8.  Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene.

Authors:  Mark Ferguson; Patricia A Henry; R Alexander Currie
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

9.  Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.

Authors:  Ahmed M I Elfiky; Mohammed Ghiboub; Andrew Y F Li Yim; Ishtu L Hageman; Jan Verhoeff; Manon de Krijger; Patricia H P van Hamersveld; Olaf Welting; Iris Admiraal; Shafaque Rahman; Juan J Garcia-Vallejo; Manon E Wildenberg; Laura Tomlinson; Richard Gregory; Inmaculada Rioja; Rab K Prinjha; Rebecca C Furze; Huw D Lewis; Palwinder K Mander; Sigrid E M Heinsbroek; Matthew J Bell; Wouter J de Jonge
Journal:  J Crohns Colitis       Date:  2022-05-10       Impact factor: 10.020

10.  The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.

Authors:  V El-Khoury; G Breuzard; N Fourré; J Dufer
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.